Evidence-based GLP-1 and GLP-1/GIP receptor agonist therapy — delivered by our specialist care team. Every patient is seen, assessed, and followed by our clinicians.
GlantHealth Metabolic Medicine is a dedicated subsidiary of GlantHealth, focused exclusively on evidence-based obesity and metabolic medicine.
Every patient is seen, assessed, and followed by our clinicians — not delegated to an algorithm.
Obesity Treatment
Both agents improve obesity, type 2 diabetes, and dyslipidemia outcomes.
Long-Term Therapy
Obesity is a lifelong condition requiring sustained, individualized management strategies.
CV & CKD Benefit
Semaglutide approved for cardiovascular risk reduction and chronic kidney disease.
Sleep Apnea
Tirzepatide approved for treatment of obstructive sleep apnea in adults.
Therapeutic Agents
Our clinic prescribes two leading Health Canada–approved incretin-based therapies, individually tailored to your clinical profile.
Wegovy® / Ozempic®
Titration Schedule
Monthly dose escalation based on tolerance
Zepbound® / Mounjaro®
Titration Schedule
Monthly dose escalation based on tolerance
The incretin therapy landscape is advancing rapidly. Three major developments are expected to reach patients in the near term — higher-dose semaglutide, oral GLP-1 agents, and the first triple-agonist retatrutide.
Compounded versions of semaglutide and tirzepatide are non-FDA-approved copies or modified versions of licensed medicines. They do not undergo regulatory review for safety, quality, or effectiveness. Our clinic prescribes branded, licensed products only.
Wrong or modified active ingredient
Compounders may use semaglutide salt forms (e.g., acetate, trifluoroacetate) that differ from the active base used in Ozempic®/Wegovy®. These salts have never been tested in clinical trials for safety or efficacy.
Quality failures identified
Follow-on injectable semaglutide samples have shown new impurities, high molecular weight proteins, trace metals, residual solvents, and oral versions with markedly lower semaglutide than label claim.
Dosing errors & overdose
Inaccurate labelling and differences in drug delivery have led to serious accidental overdoses. Vials from "clinic" or "med spa" settings carry the highest risk — concentration and volume are often non-standard.
Immunogenicity & contamination
Some compounded products have been found to contain neoepitopes, indicating potential immunogenicity risk. Contamination with unsafe additives, bacteria, or particulate matter has also been reported.
Legal status — USA
The FDA no longer permits compounding pharmacies to manufacture semaglutide or tirzepatide (shortage listing removed). Compounding of retatrutide, cagrilintide, and semaglutide salts is not lawful.
Legal status — Canada
Health Canada has raised safety and quality concerns over compounded GLP-1 products. Avoid online-sourced medications that do not require a prescription — they may be illegal, counterfeit, contaminated, or outright scams.
Red Flags — When to Be Suspicious
Our Clinic's Position
We prescribe branded, licensed Ozempic®, Wegovy®, Mounjaro®, and Zepbound® only.
Did You Know?
GLP-1 and GLP-1/GIP therapies treat the root causes of metabolic disease — obesity and insulin resistance — producing downstream benefits across multiple organ systems.
Fatty Liver Disease
MASLD / MASH
Both drugs deliver major hepatic benefits. Semaglutide 2.4 mg improves steatohepatitis and fibrosis in MASH F2–F3. Tirzepatide shows MASH resolution rates of 44–62% vs ~40% for semaglutide. Now classified as MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease).
Obstructive Sleep ApneaOSA
Tirzepatide: FDA-approved Dec 2024 for moderate-to-severe OSA in adults with obesity. ~20% weight loss → 50–80% reduction in OSA severity; CPAP adherence often improves. Semaglutide: not FDA-labeled for OSA yet, but STEP trials show ~50–60% AHI reduction, largely weight-driven.
OsteoarthritisOff-label · Weight-driven
STEP 9 trial: Semaglutide 2.4 mg in knee OA + obesity → 13.7% weight loss, 41.7-point WOMAC pain reduction vs 27.5-point placebo, with less NSAID use. Mechanism: every 1 lb lost = 4 lb less knee load; weight loss reduces IL-6 and CRP. Tirzepatide's 20–22% weight loss should exceed this, though dedicated OA trials are pending.
Insulin ResistanceCore mechanism
Both drugs improve HOMA-IR and fasting insulin. Tirzepatide's GIP receptor activation in adipose tissue increases postprandial TG uptake and improves insulin sensitivity independent of weight loss. SURPASS-2: tirzepatide improved insulin sensitivity more than semaglutide. ~38% reduction in insulin resistance markers at therapeutic doses.
PCOSOff-label · Promising
PCOS is driven by insulin resistance + obesity in 50–70% of cases. Semaglutide: small studies show improved menstrual regularity, reduced testosterone, improved ovulation. Tirzepatide: case reports of restored menses, improved insulin sensitivity — dual GIP/GLP-1 mechanism may help ovarian insulin resistance more than GLP-1 alone. RCTs underway.
PrediabetesDiabetes Prevention
Semaglutide (STEP 1): 84–93% of prediabetes patients reverted to normoglycaemia at 68 weeks. Tirzepatide (SURMOUNT-1): 95% reversal at 72 weeks with 15 mg, delaying T2D progression by 3+ years. Both essentially function as diabetes-prevention medications.
Metabolic Syndrome4/5 criteria addressed
–17 to –22% body weight · HbA1c ↓1.8–2.3% · TG ↓21 mg/dL · LDL ↓ · HDL ↑ · Systolic BP ↓5–7 mmHg. GLP-1 RAs address 4 of 5 MetS criteria: obesity, hyperglycaemia, hypertriglyceridaemia, low HDL. Tirzepatide's additional GIP receptor effect gives extra adipose/IR benefit.
Which Drug Has the Edge? — Condition by Condition
Both drugs treat the root causes — obesity + insulin resistance — so downstream benefits extend to liver, sleep, joints, ovaries, and metabolic labs. Tirzepatide generally shows larger weight loss and MASH resolution; semaglutide has more published CV and OA data.
Tirzepatide doesn't just reduce appetite. Animal and human data show it has direct actions on white, beige, and brown fat — independent of calorie intake — explaining its preferential fat-mass loss, improved body composition, and superior metabolic outcomes.
White Adipose TissueWAT
Brown Adipose TissueBAT
Beige Adipose TissueBrowning
Liver FatMASLD / MASH
Body Composition
Preferential fat-mass loss
vs fat-free mass
Fuel Shift
↑ Fat oxidation
↓ RER in obesity
Muscle Sparing
Greater fat-mass % loss
than semaglutide in T2D
Cardiometabolic
Sustained gains in BP,
lipids & glycaemia
Tissue-Level Summary
Since abnormal adipose distribution underlies obesity-related insulin resistance, reduction in overall adiposity — especially visceral and ectopic fat — improves IR through multiple mechanisms beyond simple calorie restriction.
Both agents cause some lean mass loss alongside fat loss — this is a property of significant weight loss by any method. The key question is the proportion of lean vs fat loss, and whether muscle quality and function are preserved.
Why tirzepatide spares more muscle
GIP receptor activation in adipose tissue shifts fuel use toward fat oxidation. Direct adipocyte actions (↑ lipolysis, BAT thermogenesis) mean the body preferentially draws on fat stores rather than muscle protein during weight loss.
Muscle quality improves in trials
Both drugs show improved muscle quality and physical function scores in trial data — walking speed, chair-stand tests, and grip strength do not worsen and often improve, driven by reduced fat infiltration within muscle (myosteatosis) and reduced systemic inflammation.
Risk is not eliminated — mitigate it
Lean mass loss is real, especially in older patients or those losing weight rapidly. Resistance training 2–3×/week and protein ≥1.2 g/kg/day are the strongest evidence-based mitigations. We monitor for signs of sarcopenia at every visit.
Bottom Line
Net sarcopenia risk is likely lower with tirzepatide than semaglutide, owing to greater preferential fat-mass loss (34% vs 45% lean component). Neither drug worsens frailty when combined with adequate protein and resistance exercise. This is assessed at every clinic visit.
Clinical Monitoring
Our team monitors your response at every visit to ensure safe, effective therapy.
Patient Follow-Up Log — Printable
Track your weight, dose, labs, and symptoms at every milestone: Starting · 6 Weeks · 12 Weeks · 6 Months · 1 Year · 2 Years
Symptoms typically occur within 48 hrs of initiation or dose increase. 6–10% discontinue in trials.
Weight Trajectory
% weight loss, waist circumference trends
Metabolic Health
Blood pressure, glucose, HbA1c
Mental Wellbeing
Mood, anxiety, relationship with food
Nutrition Status
Diet quality and nutrient sufficiency
Physical Activity
Exercise adherence and muscle preservation
GLP-1 / GIP Therapy · Bowel Symptoms
Tirzepatide (Mounjaro® / Zepbound®) causes both; symptoms are most prominent early and during dose escalation, then typically improve over time.
Reported Rates — Tirzepatide Clinical Trials (Label)
Diarrhea
Often lasts only 1–2 days per episode; tends to be better tolerated than semaglutide-associated constipation
Constipation
Driven by delayed gastric emptying and reduced gut motility; may require proactive management
Clinical Pearls
Clarify what "diarrhea" actually is
Because tirzepatide slows GI motility, patient-reported "diarrhea" can reflect true drug-related loose stool — or it can be stool leakage around constipation (overflow). The distinction matters for management: treating the wrong pattern can make symptoms worse.
Metformin interaction
Tirzepatide can increase metformin absorption and amplify its GI side effects. In patients taking both, reducing the metformin dose often resolves diarrhea that was attributed to tirzepatide. Always reassess concurrent medications when GI symptoms arise.
Dehydration & kidney risk
Significant diarrhea or vomiting can lead to dehydration. Dehydration-related acute kidney injury (AKI) has been reported with GLP-1 receptor agonists including tirzepatide. Patients should maintain adequate hydration and seek care if output drops or symptoms are severe.
Management by Symptom
Constipation
Daily habits first
Rescue options
Diarrhea
First-line approach
Symptom relief
When to escalate
Upper GI Side Effects
Everything you need to know — simple, visual, no jargon
Nausea & Vomiting
33–44% of patients
Why? Your stomach empties slower — food & acid sit longer. Worst at dose start & increases.
✅ Settles in weeks · Slow titration helps most
Heartburn / GERD
2–5% of patients
Why? Slow stomach = acid washes back up into the food pipe. Worse if you already have reflux.
✅ Smaller meals · Don't lie down after eating · PPI if needed
Taste Changes
Up to 2% (more with Rybelsus)
Why? Medication alters taste signals in your brain & gut. Metallic, rancid, or burning taste.
✅ Oral hygiene · Sugar-free gum · Hot water with Rybelsus
🛠️ What To Do — Step by Step
Slow Down
Never rush to the next dose while you feel sick. Slow or pause escalation.
Eat Smart
Small, low-fat meals. No eating 2–3 hrs before bed. Stay upright after meals.
Acid Control
H2 blocker (famotidine) first. If not enough → PPI (omeprazole). We prescribe.
Reduce Dose
Still struggling? Temporary hold or dose reduction — symptoms usually clear.
Switch or Stop
Refractory? We may switch you to another GLP-1 or stop. Symptoms resolve after stopping.
🚨 Call Us or Go to ER — Don't Wait
Any of the above → low threshold for upper endoscopy. These are NOT normal side effects to push through.
Common Questions
Nausea, heartburn, and taste changes are among the most common reasons people call us after starting or increasing their dose. Here's what's actually going on — in plain terms.
Why do I feel nauseous or keep vomiting?
Both semaglutide and tirzepatide slow down how quickly your stomach empties. This is actually part of how they work — it helps you feel full longer — but the trade-off is that food and acid sit in your stomach longer than usual, which causes nausea and, in some people, vomiting. This effect is strongest when you first start the medication or go up to a higher dose, and it typically settles down over a few weeks.
Can this medication cause heartburn or acid reflux (GERD)?
Yes — GERD (heartburn / acid reflux) is reported in roughly 2–5% of people on semaglutide, dulaglutide, and liraglutide, and had a significant signal across all GLP-1 medications in pharmacovigilance data. About 1 in 5 people on GLP-1 therapy develop some degree of delayed stomach emptying, and semaglutide specifically carries a notably higher gastroparesis risk compared to other weight-loss approaches. If you already have reflux or a hiatal hernia, GLP-1 therapy can make it worse — let us know before starting.
⚠️ Step 1 — Assess Severity & Red Flags First
Before managing GERD as a routine side effect, we screen for warning signs that require a low threshold for upper endoscopy:
Any of these findings moves the conversation toward specialist referral and endoscopy, not just medication adjustment.
Can reflux become serious — and when do we stop the medication?
In most people it's mild and manageable — but if vomiting is ongoing, repeated acid exposure can lead to reflux oesophagitis (inflammation of the oesophagus lining). Rare case reports have documented severe presentations requiring endoscopy. This is why we don't tell patients to just "push through." Our step approach: first, slow or pause dose escalation; if symptoms remain significant, consider a temporary hold or dose reduction. A PPI (like omeprazole) is our first-line prescription, with a mucoprotective agent added in stubborn cases. We also ask you to avoid stomach-irritating drugs concurrently — bisphosphonates (bone medications) and dabigatran (a blood thinner) in particular.
If GERD/oesophagitis is severe, or vomiting is refractory: we discontinue semaglutide. The good news is that symptoms and mucosal injury typically resolve after stopping. If you still want to stay on a GLP-1 medication, we can cautiously trial a switch to a different agent — individual tolerance varies, even though all GLP-1 therapies share a similar GI profile.
Why does food taste strange or metallic?
Dysgeusia (bad taste in the mouth) can feel metallic, salty, rancid, or even burning, and can start within a couple of weeks. Two things drive it: GLP-1 medications appear to alter taste receptor signalling directly, and slower stomach emptying causes bile and acid to reflux up, leaving a foul taste. It's more common with oral semaglutide (Rybelsus) than the injectable — if you're on Rybelsus, try taking it with hot water (46–52°C), which reduces bitterness without affecting how the drug works.
What we look for first: Before assuming it's just the medication, we check for contributing factors — uncontrolled acid reflux (treating GERD often improves the taste), oral thrush (candidiasis), dry mouth (xerostomia), and other medications you may be on (such as metformin, which can independently affect taste). Acidic and spicy foods often worsen dysgeusia, so dietary adjustments help. Good oral hygiene, saliva-stimulating measures (sugar-free gum, mints, staying hydrated) are the everyday backbone of management. If taste changes are troublesome and persistent despite addressing GERD and other contributing factors, we discuss dose reduction or switching to a different GLP-1 — weighing that against your glycemic and weight-loss benefits, keeping in mind that dysgeusia on its own is generally rare and often resolves.
Will these side effects go away on their own?
For most people — yes. GI side effects peak when you first start or go up to a new dose, then typically settle over a few weeks. Taste changes usually improve as your body adapts, though for some they persist throughout treatment. Slower dose escalation is the single most effective prevention. Never rush up to the next dose while symptoms are still active. If things aren't improving after 4–6 weeks at a stable dose, let us know — we have options beyond just waiting.
What can I do at home for heartburn and nausea?
Lifestyle habits that make the biggest difference: eat smaller, low-fat meals; avoid eating in the 2–3 hours before lying down; don't eat late at night; elevate the head of your bed slightly; stay upright after meals. For heartburn, an H2 blocker (like famotidine/Pepcid) gives quick relief. If that's not enough, talk to us about a PPI (like omeprazole) — it's our first-line prescription. Never increase your medication dose while GI symptoms are still active.
Anything I should avoid that makes this worse?
Yes — a few things can add insult to injury when the stomach is already irritated: carbonated drinks, alcohol, caffeine, fatty or spicy meals, and late-night eating all make reflux worse. Importantly, certain medications also irritate the stomach lining and should be avoided or discussed with us if you're on them — especially bisphosphonates (e.g., alendronate for osteoporosis) and dabigatran (a blood thinner). These are not necessarily stopped, but the timing and combination need to be reviewed.
Quick-Reference: What To Do
Clinical Workup · GLP-1 GI Complaints
Not every GI symptom on semaglutide is "just the Ozempic." Coeliac disease affects ~1% of the population and H. pylori prevalence is 30–50% globally — both can be missed if we anchor solely on the drug.
🔭 Upper GI Endoscopy (OGD)
Urgent suspected-cancer referral (NICE/BSG)
Consider non-urgent OGD (age ≥55)
🧫 H. pylori Testing
Test when:
Do not test for:
🌾 Coeliac Serology
Consider when:
⚙️ Practical Algorithm — GLP-1 Patient with GI Complaints
GLP-1 Therapy · Pancreatitis
Do not initiate
GLP-1–based therapy should not be started if there is a history of pancreatitis. Discuss your full medical history with your physician before beginning treatment.
Stop immediately if pancreatitis is suspected
If pancreatitis is suspected while on GLP-1–based therapy — severe, persistent abdominal pain radiating to the back, nausea, vomiting — the agent should be stopped and urgent medical assessment sought.
Do not restart if pancreatitis is confirmed
If acute pancreatitis is confirmed, the GLP-1–based agent should not be restarted. Alternative therapies should be considered in consultation with your care team.
Drug Monograph Notes
Acute pancreatitis has been reported with incretin-based therapies. Causality has not been firmly established. Prior pancreatitis may increase risk — use with caution or avoid in this population.
Acute pancreatitis has been reported with incretin-based therapies. Prior pancreatitis may increase risk — use with caution or avoid in this population.
Amylase / Lipase Elevation Alone Does Not Diagnose Pancreatitis
GLP-1 receptor agonists can cause asymptomatic elevations in amylase and lipase. These enzyme elevations have not predicted subsequent pancreatitis in clinical trials and are not sufficient to diagnose acute pancreatitis on their own. In a patient who is asymptomatic with negative imaging, current UpToDate guidance does not support a diagnosis of pancreatitis based on labs alone, and additional evaluation is generally not pursued.
Does NOT trigger stop/restart decision
DOES trigger clinical assessment
Reference: UpToDate — Acute pancreatitis diagnosis; GLP-1 receptor agonist prescribing information (Eli Lilly, Novo Nordisk).
Tirzepatide · Postmarketing Safety Data
Because tirzepatide markedly slows gastric emptying, clinically significant GI hypomotility is biologically plausible. The tirzepatide drug monograph includes postmarketing reports of intestinal obstruction and gastric outlet obstruction as gastrointestinal adverse events. GI adverse effects are most common soon after initiation and during each dose escalation.
Expected GLP-1 Type Nausea
Treat as Serious GI Pathology
Patients experiencing any of the above symptoms should not attribute them to "expected" GLP-1 nausea. Contact our clinic or seek emergency care promptly. Do not wait for your next scheduled appointment.
Perioperative Safety
When to Stop — Current 2026 Guidance
Facial plastic surgery: Many plastic surgeons and their anesthesia teams request a minimum of 2 weeks off, ideally 4 weeks, given the prolonged gastric effects seen in practice.
Key Questions
Does this apply to all surgeries?
Highest concern with general anesthesia or deep sedation. Brief procedures under local anesthetic may not require stopping. Endoscopy / EGD almost always requires stopping — gastric residue directly impairs visualization and carries aspiration risk.
What if it's emergency surgery?
If the medication cannot be held, anesthesiologists treat the patient as a "full stomach." Precautions include rapid-sequence induction (RSI) and NG tube decompression. Inform the team immediately.
What about fasting (NPO)?
Even after holding the medication, standard NPO guidelines still apply. Some centres now require a 48-hour clear liquid diet if the medication was stopped fewer than 4 weeks before surgery.
When can I restart after surgery?
Typically 1–2 days post-operatively, once oral intake is tolerated and GI function has returned. If surgery involved the GI tract, your team may wait longer. Always follow your surgical team's instructions.
What to Do — If You Have a Procedure Coming Up
Tell your surgeon and anesthesia team immediately that you are on Ozempic® or Mounjaro®. Do not wait — last-minute disclosures frequently result in procedure cancellations.
Ask three questions: Do I stop my GLP-1, and when? Do I need extra fasting or a clear liquid diet? When can I restart afterward?
If you take GLP-1 therapy for Type 2 diabetes: Do not stop without an endocrinologist's plan. The American Society of Anesthesiologists (ASA) recommends endocrine consultation to prevent perioperative hyperglycemia.
Watch for GI symptoms on the day of surgery. Active nausea, vomiting, bloating, or abdominal pain — even after holding the dose — suggests residual gastric content. Inform the team; they may use gastric ultrasound to assess and decide whether to proceed.
Evolving Guidelines
The ASA issued initial perioperative guidance in 2023. Multi-society updates in 2024–2025 suggest that select lower-risk patients may continue therapy with a 24-hour clear-liquid diet protocol rather than stopping; however, many hospitals still require a formal hold. A practical approach is risk stratification — higher aspiration risk or higher consequence of aspiration generally warrants holding one weekly dose plus additional fasting and airway precautions. Always defer to your surgical and anesthesia team, as institutional protocols vary. Guidelines continue to evolve.
Tirzepatide — Skin Reactions
A clinical overview of reported skin reactions: frequency, types, and management. Semaglutide is not prominently associated with this pattern.
Reported Frequency (Clinical Trials)
Injection-site reactions
(vs. ~0.6% placebo)
Generalised rash / hypersensitivity
(>0.1% — listed in prescribing info)
Angioedema / DRESS / anaphylaxis
(post-marketing reports)
Post-marketing: Dermatologists and obesity medicine physicians have noted an increasing volume of rash reports since Zepbound® launched. Higher doses (10 mg, 15 mg) appear to correlate with more immune-mediated effects.
Managing Injection-Site Reactions — Step-by-Step
Injection-site reactions (red welt, swelling, itching) are the most common skin side effect with tirzepatide. Most are local and self-limiting — resolving over weeks to a couple of months with the right approach. Serious systemic reactions (angioedema, anaphylaxis) require immediate cessation and emergency care.
Injection Technique
Let the pen reach room temperature
Remove from the fridge and wait 5 minutes before injecting. Cold solution is a common trigger for site reactions.
Rotate sites every injection
Abdomen, thigh, and upper arm. Never inject the same spot twice in a row. Keep a rotation log if needed.
Ensure subcutaneous depth
If the reaction is a firm nodule or induration (rather than a flat hive), the injection may not be going deep enough into the subcutaneous layer. Review needle angle and technique.
Avoid friction zones
If the reaction is localised urticaria (hive), avoid injecting areas where clothing waistbands or belts rub. Friction aggravates the response.
Stop routine alcohol swabs
Alcohol swabs at the injection site are not required for home self-injection. If eczematous skin changes appear at the site, discontinue the swab — it may be the irritant.
Topical & Systemic Treatments
Topical corticosteroid cream
Apply to the reaction site. Hydrocortisone 1% (OTC) for mild reactions; a moderate-potency steroid (e.g. betamethasone) for more pronounced induration. Apply after the injection window, not immediately before.
Oral antihistamine
A non-sedating antihistamine (e.g. cetirizine, loratadine) taken 30–60 minutes before the injection can blunt the local reaction. Continue daily for several weeks while the site reaction settles.
Flonase® (fluticasone) nasal spray — off-label topical use
Applying 1–2 sprays of fluticasone nasal spray directly to the injection site area has been used by clinicians for localised reactions. Delivers a low-dose topical steroid with minimal systemic absorption.
Topical anti-inflammatory ointment
For eczematous-type changes (dry, flaking, irritated skin), a topical anti-inflammatory ointment (e.g. tacrolimus or mild steroid ointment) can be applied between injections to soothe the skin barrier.
Cold compress immediately after injection
Applying a clean cold pack for 2–3 minutes post-injection can reduce local inflammatory response and swelling.
Stop and seek emergency care — do not "treat through" systemic reactions
If the patient develops any systemic features — facial or throat swelling (angioedema), difficulty breathing, hives spreading beyond the injection site, dizziness, or drop in blood pressure — this must be treated as a potential serious hypersensitivity reaction to tirzepatide, not a routine local reaction. Stop the drug immediately, administer epinephrine if available, and call 911. Do not rechallenge.
Most local injection-site reactions with tirzepatide resolve on their own within a few weeks to a couple of months with the measures above. If reactions persist, worsen, or spread beyond the site, contact our clinic to reassess — a switch to semaglutide may be appropriate for some patients.
Severity Spectrum & Presentation
Injection-Site Reaction
Management
Delayed Hypersensitivity
Management
Systemic / Anaphylaxis
Management
Seek Emergency Care if Any of These Occur
What to Track at Clinic — If You Have a Rash
Onset timing
After first dose, or after a dose increase? First few days vs. weeks later?
Location
Injection site only, or widespread on trunk/limbs?
Associated symptoms
Fever? Facial swelling? Shortness of breath? These point to systemic reaction.
Antihistamine response
Did OTC antihistamines improve or resolve the rash? Helps classify severity.
Sources: Tirzepatide (Mounjaro®/Zepbound®) prescribing information (Eli Lilly). Clinical trial data: SURMOUNT program. Post-marketing observation reflects dermatology and obesity medicine community reports. Clinicians noting similar clusters are encouraged to file reports with Health Canada and/or FDA MedWatch.
One of the most under-discussed side effects — here's a practical, tiered approach from foundation to prescription options.
Long-Term Safety
GLP-1 RAs are associated with modest hair loss, dysesthesia/paresthesia, and rare pulmonary aspiration under anesthesia (due to delayed gastric emptying). Over 1–5 years, GLP-1 RAs show net cardiovascular and renal benefit with manageable, mainly GI and gallbladder-related toxicities — and several rare but important safety signals that warrant individualized risk–benefit assessment. We routinely offer counselling and monitoring for all of these.
🦋 Thyroid C-Cell Tumour Risk
Due to rodent thyroid C-cell tumour data and uncertain human relevance, tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.
🔥 Pancreatitis
Acute pancreatitis has been reported with GLP-1 receptor agonists; causality is not established. Therapy should be stopped if pancreatitis is suspected and not restarted if confirmed. GLP-1-based therapies should not generally be initiated in patients with a prior history of pancreatitis.
🫀 Gallbladder & Biliary Disease
GLP-1 RAs are associated with increased risk of gallbladder and biliary disease, with higher risk at higher doses, longer duration, and when used for weight loss. For tirzepatide, increased risk has been reported after more than 26 weeks of therapy.
🫘 Kidney Injury — Dehydration Risk
Acute kidney injury has been infrequently reported, typically in the setting of severe GI adverse effects and dehydration. Kidney function monitoring is advised when significant GI symptoms are present, especially in patients with pre-existing CKD.
🧠 Severe GI Complications
When used for weight reduction, GLP-1-based therapies have been associated with more severe GI risks including intestinal obstruction and symptomatic gastroparesis. GI effects are most common at initiation and each dose escalation, and may improve over time with slower titration.
👁 Diabetic Retinopathy (if diabetes)
For patients with diabetic retinopathy, dose titration should be slow and retinal screening should be performed within 6 months of starting, especially with marked baseline hyperglycemia. Rapid glucose lowering may transiently worsen retinopathy.
⚡ Dysesthesia / Paresthesia
Dysesthesia, paresthesia, and cutaneous dysesthesia (abnormal skin sensations — burning, tingling, electric-like) have been reported with semaglutide. Incidence is dose-dependent and increases at higher doses. Patients should be counselled to report new or worsening skin or nerve sensations, particularly during dose escalation.
Practical Monitoring Approach
Before Starting
Ongoing Monitoring
What to expect if stopping: Discontinuation of GLP-1/GIP therapy is associated with weight regain — similar patterns have been observed after stopping tirzepatide or semaglutide, with reversal of cardiometabolic benefits. Long-term treatment planning is part of every patient's care at GlantHealth.
Large cohort studies and RCT meta-analyses do not show an overall increase in cancer incidence with GLP-1 receptor agonists. Multiple studies suggest a neutral or modestly protective effect — likely driven by weight loss, reduced insulin/IGF-1, and lower systemic inflammation, rather than direct anti-tumour activity. Important exceptions and unknowns remain.
Key Hazard Ratios — 1.1 Million Patient Cohort Study
🥞 Pancreatic Cancer
Early fear not supported. Initial concern arose because GLP-1s promote β-cell proliferation. Meta-analyses and 8-year follow-up data show no increased risk. Some studies report HR 0.23 vs insulin — likely confounded by insulin's own risk profile. FDA and EMA reviewed the data and concluded evidence was insufficient to confirm increased pancreatic cancer risk; monitoring continues.
🦋 Thyroid Cancer (C-Cell)
FDA black-box warning is based on rodent studies — liraglutide and semaglutide caused C-cell tumours in rats. Crucially, human thyroid C-cells do not express GLP-1 receptors, making the rodent findings mechanistically difficult to extrapolate. Human data are conflicting: one cohort found HR 1.70 with liraglutide; others find no association. Medullary thyroid cancer is very rare (0.2 per 100,000). GLP-1/GIP agents are contraindicated if you or a first-degree relative have a history of medullary thyroid cancer or MEN2 syndrome.
🌸 Breast & Endometrial
Multiple studies suggest reduced risk. Target-trial emulation: endometrial and ovarian cancer HR significantly below 1.0. Tirzepatide is now in dedicated trials for early breast cancer and endometrial cancer. A preclinical mouse study found tirzepatide shrank breast tumours — human trial data are pending. Likely driven by oestrogen metabolism improvement via adipose tissue reduction.
🔴 Colorectal Cancer
Reduced risk with prolonged use in most observational data. However, a network meta-analysis flagged a signal for increased colorectal tumours at high-dose semaglutide, and one Mendelian randomisation study raised concern. The signal is not consistent across studies. For most patients the overall GI cancer HR remains well below 1.0 (0.45 for semaglutide vs non-users in the 1.1M cohort).
🫀 Liver Cancer
Protective in diabetic and NASH/MASLD models. HR 0.47 vs insulin in T2D cohorts. Mechanism: reduction of hepatic steatosis, inflammation, and fibrosis — all precursors of hepatocellular carcinoma. Consistent with the broader MASLD benefit data. Effect in metabolically healthy non-T2D patients is less studied.
🩸 Haematological
Highly variable across agents in early data. Dulaglutide showed OR 2.18 (higher risk) in one pilot analysis; tirzepatide showed OR 0.14 (lower risk) in the same analysis. These are small, exploratory studies — no conclusions can be drawn. Active pharmacovigilance is ongoing.
Absolute Contraindications Related to Cancer Risk
Important Caveats & Unknowns
GLP-1 receptor agonists are a powerful tool — but the same mechanisms that make them effective can pose serious risks for patients with a current or past eating disorder. This requires careful clinical consideration before and during treatment.
If an eating disorder is identified during treatment, the prescribing clinician should be informed immediately so that dosing and monitoring can be reassessed.
Lifestyle Integration
What you preserve — not just what you lose — defines the quality of your outcome. Muscle, metabolic rate, and functional capacity must be actively protected throughout treatment.
Emerging research shows that a meaningful portion of weight lost on these medications comes from lean mass. In some cases, that number is substantial.
While not all lean mass is muscle, the implications are clear. Without intervention, individuals — particularly older adults — may lose strength, functional capacity, and metabolic resilience alongside body weight.
That is not a side effect. That is a defining issue — and a red flag for our healthcare system.
Muscle is foundational to how we move, how we age, and how we maintain independence. Loss of muscle mass is linked to increased risk of falls, frailty, and long-term health decline. In a country with an aging population, this is not acceptable collateral damage.
It must sit at the centre of how we evaluate treatment, define success, and design care.
A significant fraction of GLP-1 weight loss is lean mass. We actively monitor body composition at every visit and prescribe protein targets (≥1.2–1.5 g/kg/day) and resistance training (2–4× per week) as core elements of therapy — not optional add-ons.
Strong appetite suppression compresses the window for adequate intake. Every meal must count. Focus on lean proteins, micronutrient-rich whole foods, healthy fats, and fibre — not simply eating less.
Clinical trials confirm that walking alone does not preserve lean mass during GLP-1 weight loss. Progressive, whole-body resistance training is the only exercise modality shown to reduce GLP-1–associated muscle loss.
Outcomes improve when dietitians, exercise specialists, and clinicians work together. We facilitate referrals and coordinate across disciplines — because obesity management is too complex for a single provider working alone.
GLP-1 therapy creates a powerful caloric deficit — and without a structured plan, lean mass pays the price. This is how we address it.
What the evidence shows about muscle mass, physical performance, and exercise behaviour on GLP-1 receptor agonist therapy — and what this means for GlantHealth clients.
Some lean mass reduction is a normal part of any significant weight loss — whether achieved through lifestyle change, bariatric surgery, or pharmacotherapy. GLP-1 medications are not uniquely responsible for muscle loss; the effect is proportional to total weight lost and is seen across all effective weight loss interventions.
For most patients, the benefits of weight loss substantially outweigh the concerns about modest lean mass changes. MRI substudies — including tirzepatide trials — show meaningful reductions in intramuscular fat alongside only proportional changes in muscle volume. The overall picture is metabolic improvement, not muscle wasting.
Resistance training and adequate protein intake are the two most effective strategies for preserving lean mass during GLP-1–assisted weight loss. Meta-analyses find no clinically meaningful changes in grip strength, functional capacity, or cardiorespiratory fitness in patients who remain active — physical performance is preserved when these two elements are in place.
GLP-1 medications often markedly increase patients' activity levels as a practical consequence of weight loss. As weight drops, exercise becomes easier, less painful, and more comfortable — a consistent pattern seen across patients who lose weight through lifestyle change, pharmacotherapy, surgery, or any combination of these approaches.
Regular exercise training raises late-phase postprandial GLP-1 levels by approximately 25% compared with usual activity — and GLP-1 therapy does not attenuate this effect. The body's own exercise-induced GLP-1 signalling remains fully intact alongside medication, meaning the two work together rather than competing.
GLP-1 receptor agonists do not impair exercise tolerance. As weight and cardiometabolic health improve, physical activity typically becomes easier — and the benefits of exercise remain fully intact.
Menopause reshapes body composition in ways that make metabolic management harder — and more important. Here is what the evidence says about GLP-1 therapy for women in this stage of life.
Menopause is associated with significant shifts in body composition — fat mass increases while lean mass decreases, with weight gain and increased central fat distribution occurring particularly in early postmenopausal years.
The loss of estrogen accelerates the shift of fat from peripheral depots to visceral (abdominal) adipose tissue — the fat most strongly linked to cardiovascular risk, insulin resistance, and metabolic disease.
These hormonal changes can make weight management substantially more difficult, even for women who have maintained a stable weight throughout their adult lives.
Menopausal women do lose weight with GLP-1 therapy — though weight loss may be somewhat less than in younger women. Individual response varies considerably, and many women achieve clinically meaningful results.
The goal of GLP-1 therapy is not necessarily to reach a normal BMI. The primary aim is to reduce the visceral adiposity that is driving metabolic health problems — even a 5–10% reduction in body weight produces meaningful clinical benefit.
GLP-1 receptor agonists target visceral fat preferentially compared with diet-alone interventions — precisely the fat depot that poses the greatest health risk during and after menopause. For many women, this means large gains in overall health, quality of life, and metabolic well-being even before the scale reflects the full benefit.
Estrogen plays a critical role in maintaining bone density. Menopause accelerates bone loss, and significant weight loss — through any method — can compound this effect. This is an important consideration when planning GLP-1 therapy in postmenopausal women.
Resistance training is particularly valuable here — it stimulates bone remodelling and helps preserve bone mineral density alongside muscle mass. It is one of the most effective non-pharmacological strategies for bone health in this population.
Adequate calcium and vitamin D intake should be reviewed as part of care for menopausal women on GLP-1 therapy. Discuss supplementation needs with your clinician.
Some GLP-1 side effects share common features with menopausal symptoms, which can make attribution difficult. Symptoms to be aware of include:
If symptoms feel worse than expected, or are new in character, let your clinician know. Tracking onset in relation to dose changes helps distinguish medication effects from hormonal ones.
Studies show that women aged 50–70 gain muscle at similar rates to younger women when they begin a resistance training programme. Age is not a barrier to building lean mass — it makes starting all the more worthwhile.
The goal for menopausal women on GLP-1 therapy is fat loss — not just weight loss. Protecting and building muscle while fat is reduced improves metabolic rate, physical function, bone density, and long-term independence.
As weight drops with GLP-1 therapy, exercise typically becomes noticeably easier, less painful, and more comfortable — creating a practical window to begin or increase resistance training that may not have been accessible before.
Your clinician will check in with you before each dose up-titration. Not every patient needs — or tolerates — the maximum dose. The right dose is the one that provides meaningful benefit with acceptable side effects, not necessarily the highest available.
Many patients notice meaningful changes in hunger and food noise well before reaching a higher dose. If appetite is well-controlled and weight loss is progressing, a lower maintenance dose may be entirely appropriate.
GLP-1 therapy can help counteract some of the hormonal weight gain associated with menopause — but treatment decisions should account for the whole picture, including bone health, cardiovascular risk, and quality of life.
The goal isn't a number on the scale. It's reducing the visceral fat driving health risk, preserving muscle, protecting bone, and helping you feel better in your body — at this stage of life, and beyond.
Obesity requires lifelong treatment. Discontinuation leads to regain of ~two-thirds of lost weight within one year, and may worsen T2DM and hypertension. Our team works with you on individualized long-term options:
All decisions consider: clinical need, insurance coverage, cost, and your long-term health goals.
Home Exercise Guide
Resistance training is non-negotiable on GLP-1 therapy. These are clinician-reviewed equipment choices suited to patients at all fitness levels — from low-impact cardio to progressive strength work.
GlantHealth Metabolic Medicine does not partner with, endorse, or receive compensation from any of the companies listed below. Products are suggested solely on the basis of clinical suitability for patients on GLP-1 therapy. Always consult your clinician before starting a new exercise programme.
~25–40% of GLP-1 weight loss is lean mass
Without resistance training, you lose muscle — not just fat
Resistance training is the only proven fix
Walking and light cardio do not preserve lean mass in clinical trials
Home equipment removes the gym barrier
Consistency matters more than intensity — make it frictionless
Life Fitness Symbio Recumbent Cycle
Step-through design makes mounting easy at higher BMI. Dual-action arm handles add upper-body engagement. Multiple resistance levels for progressive overload.
Spirit Fitness CR1000ENT Recumbent Bike
Commercial-grade durability in a home footprint. Large seat, back support, and easy entry — well-suited for patients with limited mobility or recovering from deconditioning.
Matrix Total Body Cycle
Combines arm and leg cycling to maximise caloric output and engage more muscle groups simultaneously. Useful for patients who cannot weight-bear for long periods.
Martoni Cardio Speeder
Compact seated cardio unit with variable resistance. Good entry-level option for patients beginning exercise or working within nausea limitations post-injection.
Precor Breakaway™ Treadmill (Slat-Belt)
Slat-belt design distributes impact more evenly than traditional belts — significantly easier on knees, hips, and ankles. More natural running gait. Suitable for higher-weight users.
Matrix ClimbMill — Touch XL Console
Stair climber format with continuous rotating steps. Exceptional for glute, quad, and hamstring activation — directly targets muscles prone to atrophy on GLP-1 therapy. Touch XL console tracks workout metrics.
Precor Glutebuilder Selectorized Pendulum Kickback
Targets the gluteus maximus and hamstrings — muscle groups heavily affected by GLP-1–associated lean mass loss. Selectorized weight stack allows precise, safe progression. Pendulum motion reduces joint stress compared to cable kickbacks.
Resistance Vest
Adds distributed load (typically 5–25 kg) to any bodyweight movement — squats, lunges, stair-climbing, walking. Inexpensive, space-efficient, and progressive. GLP-1 clinical guidance specifically recommends progressive resistance — a vest is the most accessible way to achieve this at home.
Resistance Bands
Light, medium, and heavy colour-coded bands for progressive resistance. Covers rows, curls, presses, and leg work in a single inexpensive, portable kit. Ideal for GLP-1 patients at any fitness level — gentle enough to start with, strong enough to keep challenging muscles as strength returns.
Dumbbells (Light Fixed-Weight Set)
Start with 2–5 kg for upper body work — bicep curls, shoulder press, and lateral raises that target the arm and shoulder muscles most prone to atrophy on GLP-1 therapy. Fixed-weight dumbbells are safer and simpler than adjustable sets for beginners, with no plates to load or pins to set.
BOSU NexGen™ Pro Balance Trainer
Unstable surface training improves proprioception, ankle stability, and core engagement. Dual-sided use (dome up or flat side up) varies difficulty. Especially useful as rapid weight loss alters balance and gait.
Freemotion Pilates Reformer MS-01S
Spring-resistance reformer for full pilates, yoga, and Lagree-style workouts at home. Delivers resistance-based movement in a low-impact, joint-friendly format. Supports the deep postural muscles that protect the spine during rapid body recomposition.
InBody Dial H30
The InBody H30 is the home-use counterpart to the clinical InBody devices used in our clinic. Uses the same bioelectrical impedance analysis (BIA) technology to provide segmental body composition data — skeletal muscle mass, body fat percentage, and total body water — directly on your smartphone via the InBody app.
Home Exercise Guide · Workout Blueprint
A deceptively simple combination that covers all three pillars of GLP-1 exercise: muscle preservation, cardiovascular base, and joint-friendly movement. Here is why it works — and how to structure it.
Muscle preservation — the non-negotiable priority
Studies show 25–40% of GLP-1 weight loss can be lean mass without strength work. Bands and dumbbells apply progressive resistance to your muscles while the medication reduces your appetite — keeping your metabolism protected as the scale moves.
Incline walking + bands = loaded cardio without joint stress
Incline treadmill walking already activates glutes and hamstrings significantly more than flat walking. Add a resistance band above your knees and you recruit the glute medius — improving hip stability and burning more calories without high-impact loading. Ideal when GLP-1 fatigue makes intense cardio unrealistic.
Adapts instantly to how you feel on any given day
Bands and dumbbells let you scale resistance in seconds — no plates to load, no machines to adjust. On nausea days, drop the weight. On good days, increase it. Steady-state incline walking is also consistently better tolerated than HIIT when GI symptoms are present.
Goblet Squat Dumbbell + band above knees · 12 reps
Band cues knees to drive outward — protects form when GLP-1 fatigue affects coordination
Banded Romanian Deadlift Light dumbbells + band around feet · 10 reps
Targets hamstrings and glutes — critical for metabolic health and posture during weight loss
Resistance Band Row Band anchored, dumbbell in other hand · 12 reps/side
Counteracts the postural changes that accompany rapid weight loss
Incline Treadmill Walk 5 min · 5–8% incline · 2.5–3.0 mph · band above knees
You will feel this in your glutes. Hold the rails lightly if GLP-1 causes dizziness — no shame in that
Exercise 1–2 hours after your largest meal of the day. Keep sessions to 30–45 minutes maximum in the first weeks — a short session you complete beats a long one you abandon.
Avoid floor-lying exercises on high-nausea days. Standing band work and incline walking are consistently better tolerated than floor-based abdominal exercises or anything that shifts your centre of gravity repeatedly.
GLP-1 medications reduce thirst cues alongside appetite. Sip electrolytes before incline work — you sweat more than you realise you are thirsty for.
Aim for 30–60 g protein within two hours of finishing. During rapid weight loss, post-workout nutrition is your primary lever for protecting lean mass — do not skip it.
Best starting position. Strongest glute activation with the least change to your natural gait. Start here.
Significantly harder. Requires shorter steps and a lighter band. Progress to this once above-knee feels easy.
Activates calves and shins. Useful if you experience foot tingling or numbness — a reported sensation in some GLP-1 users.
Muscle is your metabolic insurance policy. The medication is a tool — exercise is what makes the results last.
Not sure where to start? Our clinical team can help you build a realistic home exercise plan matched to your current fitness level, nausea pattern, and GLP-1 titration schedule. Message us on WhatsApp →
GLP-1 Nutrition Guide
Joint society guidance for GLP-1 users: prioritise lean proteins, distribute intake across the day, and pair with resistance training to protect muscle.
Each portion below delivers approximately 20 g of protein — your per-meal minimum on GLP-1 therapy.
Steak
4 oz
Tuna
3 oz
Green Peas
3 cups
Chicken Breast
3 oz
Eggs
4 eggs
Greek Yogurt
8 oz
Chickpeas
3 oz
Kidney Beans
3 cups
Cottage Cheese
¾ cup
Every amount below delivers approximately 20 g of protein — your minimum target per meal on GLP-1 therapy. Save this as your reference.
Chicken Breast
cooked, skinless
Turkey Breast
cooked, no skin
Beef Sirloin
cooked, lean
Pork Tenderloin
cooked
Shrimp
cooked, peeled — ≈ 8–9 large
Salmon (Atlantic)
cooked fillet
Canned Tuna
in water, drained — ½ can
Cod / Tilapia
cooked, white fish
Canned Sardines
in water — ≈ 4–5 fillets
Whole Eggs
large — 6 g each
Egg Whites
large — 3.6 g each
Greek Yogurt (0% fat)
≈ ¾–1 cup
Cottage Cheese (1%)
≈ ¾ cup
Whey Protein
1 standard scoop
Skyr / Icelandic Yogurt
higher protein than Greek
Tempeh
cooked — complete protein, fermented
Firm Tofu
cooked or raw
Edamame
shelled, cooked — ≈ 1½ cups
Lentils (cooked)
≈ 1½ cups — also high fibre
Black Beans (cooked)
≈ 2 cups — also complex carb
Chickpeas (cooked)
≈ 1¾ cups — good zinc source
Hitting your protein target on GLP-1 therapy means building it into every meal. Each example below delivers approximately 20–30 g of protein in a realistic, GLP-1–friendly portion.
Breakfast
~24 g protein
3 scrambled eggs + ½ cup Greek yogurt
Lunch
~28 g protein
85 g grilled chicken + ½ cup lentils
Dinner
~26 g protein
130 g salmon fillet + ½ cup quinoa
Snacks
~20 g protein
¾ cup cottage cheese + 1 hard-boiled egg
Complete amino acids — most efficient muscle support
Protein-rich with probiotic gut benefits
High biological value protein in small portions
Plant proteins with fibre + iron
Protein + micronutrients — energy-dense
When whole-food intake is insufficient
Breakfast
Lunch
Dinner
Snacks
Protein Smoothie (when appetite is very low)
Protein powder + 2 tbsp ground flax + soy or almond milk + strawberries or banana. Plant-based powders (pea, pumpkin seed) if avoiding dairy. Aim for ≥ 20 g protein per serving.
These spike blood sugar, worsen nausea (by slowing gastric emptying further), and reduce the metabolic benefit of therapy.
Sugary Drinks
Spikes glucose rapidly; no satiety signal
White Bread & Pasta
High glycaemic — blunts metabolic improvements
Fried Foods
High fat delays gastric emptying → severe nausea
Baked Goods & Pastries
Sugar + fat combination — worst for GI symptoms
Ultra-Processed Foods
Displace nutrient-dense options on reduced appetite
Alcohol
Worsens nausea; empty calories; liver stress
Eat Protein First
You'll feel full quickly — prioritise protein before carbs or vegetables so you always hit your protein target before satiety kicks in.
Small, Frequent Mini-Meals
3 small meals + 1–2 protein snacks works better than large meals. Stop eating at the first sign of fullness — don't push through.
Pair Protein with Fibre
Fruits, vegetables, and legumes help with constipation — a common GLP-1 side effect. High-fibre foods also naturally boost GLP-1 and satiety.
Choose Low-Fat Proteins
High-fat foods worsen nausea because GLP-1s slow gastric emptying. Lean meats, low-fat dairy, and egg whites are easiest on the stomach.
Stay Hydrated
Drink water between meals, not with meals (which takes up stomach space). Target 2–2.5 L/day. Hydration supports kidney function and reduces constipation.
Lift Weights — Non-Negotiable
Protein alone does not protect muscle mass. Resistance training 2–4× per week is required to prevent sarcopenia. Talk to us about a referral to an exercise specialist.
Protein First, Always
Eat protein at the start of every meal before anything else. Satiety arrives quickly on GLP-1 therapy — if you fill up on carbs first, protein targets will not be met. Aim for 20–40 g per eating occasion.
Actively Track Hydration
GLP-1s suppress thirst as well as hunger. Target 1.5–2 L water daily — drink between meals rather than with them, to avoid competing with limited stomach capacity. Dehydrated muscle breaks down faster.
Time Your Workouts Strategically
Many patients feel least nauseous 4–6 hours after injection, or in the late afternoon. Scheduling strength training at your lowest-nausea window dramatically improves consistency and performance.
Walking Alone Is Not Enough
Clinical trials confirm: walking fails to preserve lean mass during GLP-1 weight loss. Resistance training — progressive, whole-body, 2–4× per week — is the only exercise modality shown to reduce GLP-1–associated muscle loss.
Collagen Peptides — Adjunct Only
10–20 g/day of collagen peptides (stirred into coffee or shakes) may support skin elasticity when whole-food protein is insufficient. They are not a substitute for dietary protein and have no proven effect on facial fat compartments specifically.
Unprocessed, Nutrient-Dense First
Within a reduced appetite, every bite must count. Prioritise lean meats, dairy, eggs, legumes, nuts, and whole foods over ultra-processed options. Nutrient density — not just protein grams — protects against micronutrient deficiency.
Red Flag: You May Not Be Eating Enough
Dizziness, extreme fatigue, or mood swings while on GLP-1 therapy almost always signal insufficient intake — not the drug. If strength training makes you feel markedly worse rather than better, scale back intensity immediately and focus on hitting protein targets first. Contact our clinic before adjusting your medication dose.
GLP-1s kill appetite so effectively that many patients drift into eating just once a day. This feels easier — but creates serious nutritional, muscular, and metabolic risks.
Clinical Position
Multiple small, nutrient-dense meals with dietitian support — preferred over OMAD
Accelerated Muscle Loss
25–40% of GLP-1 weight loss is already lean mass. The body needs protein every 3–5 hours to prevent breakdown. OMAD creates a 19+ hour fasting window — long enough to trigger muscle catabolism. Trials show ~10% skeletal muscle loss (~6 kg over 68–72 weeks) even with adequate eating patterns.
Worse "Ozempic Face" & Skin Sagging
No steady supply of amino acids means less collagen repair. Facial imaging shows ~7% midfacial volume loss per 10 kg lost. OMAD amplifies this by worsening protein and micronutrient shortfalls — soft-tissue deflation hits harder with rapid loss plus low protein.
Micronutrient Deficiency
GLP-1 patients are commonly already low in vitamin D, B12, iron, folate, zinc, calcium, and magnesium before starting therapy. Hitting 80–120 g protein, adequate fibre, and all micronutrients in a single small-capacity sitting is rarely achievable — clinical reviews recommend structured dietitian-supported meal patterns.
Worse GI Side Effects & Dehydration
GLP-1s already cause nausea, early satiety, and vomiting. A large single meal on a slow stomach dramatically worsens nausea, reflux, and constipation. Erratic hydration across the day — with fluids bunched around one meal — is linked to acute kidney injury in GLP-1 users.
Metabolic Rate Crash ("Skinny-Fat")
Severe restriction without adequate protein and resistance training trains the body to preserve fat and burn muscle. The result: lower BMR, metabolic adaptation, and a much higher risk of weight rebound when medication is reduced or stopped.
Protein Target Physically Impossible
Guideline-level protein (≥1.2–1.5 g/kg/day) requires 80–140+ g/day for most adults. With strong appetite suppression and reduced stomach capacity, fitting this into one meal is physiologically very difficult — particularly in older or smaller patients.
If any of these apply, contact our clinic before adjusting your dose — these symptoms almost always signal insufficient intake, not medication failure.
If You Can Only Manage One Meal — Make It Count
Target: ≥80–100 g protein · 25 g fibre · all key micronutrients — this is your minimum floor
Protein Pre-Load
30 g whey or casein + collagen peptides — pre-loads amino acids before the meal, easier than solids when nauseous
~30 g proteinRecovery & Hydration
Electrolytes + fibre supplement if short · Space fluids throughout the day, not just with the meal
Stay hydratedAbsolute Minimum Daily Floor — Can't Force More Meals?
Preferred Pattern on GLP-1 Therapy
Multiple small, nutrient-dense meals and snacks distributed across the day — prioritising high protein (≥1.2–1.5 g/kg/day), adequate fluids between meals, and micronutrient-rich whole foods. Intensify monitoring when weight loss exceeds 10% in the first 6 months. Dietitian involvement is recommended for patients struggling with intake adequacy.
No clinical trial shows that specific "collagen foods" prevent facial fat loss — that is driven by rate of weight loss and lean mass. What is supported: adequate total protein, key micronutrients, and resistance training. These nutrients help your body build and maintain collagen.
Vitamin C
Required for collagen synthesis — rate-limiting step
Protein & Key Amino Acids
Collagen's structural building blocks
Zinc
Activates collagen-producing enzymes
Copper
Cross-links collagen and elastin fibres
Collagen Disruptors — Limit
Accelerate breakdown, worsen GI side effects
Sample Collagen-Support Day
~90 g protein · Rich in C, zinc & amino acids
GLP-1 Nutrition Guide · Dietary Fibre
Fibre is not optional on GLP-1 therapy. It fights constipation (the most common side effect), protects muscle and skin during rapid weight loss, and helps sustain the natural GLP-1 response when you eventually taper or stop medication. The challenge: a suppressed appetite makes hitting 25–38 g/day genuinely difficult. This guide shows you how.
🥣 Soluble & Fermentable
Slows gastric emptying, enhances satiety signalling, and directly stimulates endogenous GLP-1 release — essentially complementing your medication.
🍚 Resistant Starch
Resists digestion in the small bowel and ferments in the colon — feeding the gut bacteria (especially Akkermansia) that produce short-chain fatty acids and drive endogenous GLP-1 secretion.
🧅 Prebiotic Fibre
Selectively feeds Akkermansia, Bifidobacterium, and other microbes that amplify the GLP-1 response and reduce systemic inflammation.
📊 How Much You Need
Ramping too fast on GLP-1 therapy is a reliable way to trigger severe constipation. Slow, steady increase wins.
💊 If You Are Already on Ozempic® or Mounjaro®
Getting Fibre In When Appetite Is Near Zero
On GLP-1 therapy, you may be comfortably eating 300–500 kcal/day and feeling full. Here is how to hit your fibre targets without forcing food volume.
1 — Liquid & Gel Fibre First
Easiest to tolerate; minimal stomach volume
2 — Layer Fibre Into Protein Foods
You are already forcing protein — add fibre to the same meal
Compact Reference — Fibre + Protein Dual Sources
Timing Strategies
When Higher Fibre May Not Be Appropriate
A high-fibre diet is contraindicated or requires close monitoring in certain clinical situations. Discuss with your clinician before aggressively increasing fibre if you have:
What to Avoid When Appetite Is Low
🚨 Discuss With Your Clinician
The Clinical Bottom Line
On GLP-1 therapy, treat fibre as a clinical tool rather than a dietary afterthought. Prioritise soluble, gel-forming fibre sources — psyllium, chia, oats, cooked legumes. Pair every fibre dose with protein to preserve muscle. When appetite makes food-based intake difficult, a combination of 10 g from targeted supplements plus 15 g from food consistently outperforms struggling to hit 25 g from food alone. Whole, minimally processed sources should lead; engineered "GLP-1 friendly" packaged products should follow.
Digital Support
Regulators mandate lifestyle support alongside GLP-1 therapy. Digital health coaching tools help patients stay adherent, motivated, and safe between clinic visits.
HWC Improves Adherence
Health and wellness coaching (HWC) significantly improves GLP-1 medication persistence and long-term weight-loss maintenance compared to medication alone.
Regulatory Mandate
Health Canada and the FDA require lifestyle intervention to be delivered alongside GLP-1 pharmacotherapy — it is not optional.
4 Core Coaching Targets
Effective digital tools address: diet quality, physical activity, medication management, and coping skills — not just weight on a scale.
Long-Term Focus
The evidence favours sustained structured coaching over short "GLP-1 boot camps." Obesity is a lifelong condition — support must match that timeline.
Simple Life combines AI-guided intermittent fasting with personalised weight-loss coaching. Its onboarding survey builds a custom plan around your goals, schedule, and dietary preferences — covering fasting windows, nutrition, hydration, and habit tracking.
Cal AI uses your phone camera to identify and log food in seconds — no manual entry, no barcode scanning. Point, shoot, and your macros are tracked. Built for people who want effortless nutrition logging without the friction that kills consistency.
Structured Health & Wellness Coaching (HWC) principles — not generic weight-loss advice
Medication Persistence Support
Target continued adherence and safety — help patients navigate dose escalation, manage side effects, and understand why persistence beyond 3–6 months is critical for outcomes.
Dietary Behaviour Change
Protein-first eating, portion awareness, food quality education, and GI symptom management — not just calorie counting. Coaching should teach skills, not just log numbers.
Physical Activity Progression
Structured resistance training guidance, step-count targets, and progressive overload plans to prevent muscle loss and metabolic adaptation during weight loss.
Coping Skills & Psychological Support
Address emotional eating, body image, food noise reduction, and the psychological adjustment of managing a chronic condition — areas medication alone cannot address.
Operationalise, Don't Just Educate
The best digital tools go beyond information delivery — they prompt action, track behaviour, celebrate wins, and create accountability loops between patient and clinician.
Long-Term Commitment Over "Boot Camps"
Short-duration GLP-1 programs are not supported by evidence. Obesity requires long-term management — coaching tools should build habits that persist after medication dose is reduced or discontinued.
The following platforms use artificial intelligence to personalise strength and fitness programming — directly relevant for GLP-1 patients who need progressive resistance training to prevent muscle loss. GlantHealth does not partner with or receive compensation from any of these companies.
Fitbod
AI Strength App · $8–16/month
Builds individualised workouts based on available equipment, muscle recovery state, and training goals. Automatically handles progressive overload — adjusting sets, reps, and load from logged performance. Rated #1 for muscle building in 2026.
Future App
Human Coach + AI · $199/month
Pairs each user with a real human coach — AI handles programming adjustments between sessions based on performance, recovery, and soreness data. Coach texts you daily. Integrates with Apple Watch and Android trackers.
HOTWORX TrainingTRAX
Launched April 2026 · Sweat Elite members
AI-powered personal training system embedded in the HOTWORX Burn Off App. Generates a Body Vision avatar from a selfie, builds customised 90-day plans, and adapts using a Burn Rate algorithm across infrared sauna and FX Zone workouts. 800+ locations globally.
Also Launching AI in 2026
Vasa Fitness
AI personal training app with Demotu — trainer-prescribed workouts between gym sessions
NYSC MYCO
First major U.S. gym chain with AI embedded at membership level, built with Zing Coach
SHRED App
AI virtual trainer adapts to dumbbells, bands, and bodyweight — ideal for home-only patients
GlantHealth Clinic Position
We do not endorse or have a financial relationship with any of the apps listed above. They are referenced as examples of digital coaching tools that align with evidence-based HWC principles. Our team provides direct lifestyle counselling at every visit. For patients who benefit from additional between-visit digital support, we are happy to discuss which tools may complement your care plan. Contact us via WhatsApp: +1 705-280-6886.
Home Exercise Guide · Motivation & Low Mood
GLP-1 therapy suppresses appetite — but it does not protect your muscles, maintain your fitness, or prevent weight regain when you eventually taper. Exercise does those things. The challenge is that fatigue, nausea, and low mood (which frequently co-exist with obesity) make starting feel impossible. This section reframes how you approach movement, grounded in what clinicians actually observe after years of working with patients on these medications.
GLP-1 Therapy May Actually Make Starting Easier
Emerging evidence suggests semaglutide reduces the perceived effort cost of physical tasks — participants in one study were measurably more willing to exert physical effort for reward, driven by reduced effort discounting. In patients with depression or low motivation, GLP-1 treatment may improve what clinicians call "effort-based decision-making." The drug may be quietly lowering the internal barrier that makes the couch feel safer than the shoes.
Exercise Is a Clinical Antidepressant
Resistance training, aerobic exercise, and even voluntary low-intensity movement consistently reduce anxiety and depressive symptoms in clinical studies — with effects comparable to medication in mild-to-moderate depression. You do not need to feel motivated before you move. In practice, motivation tends to follow movement, not precede it. The first two minutes are the medicine.
Water-Based Movement
Pool walking and aqua movement are among the most effective entry points for GLP-1 patients. The water offloads joint stress significantly — which matters when early weight loss has not yet reduced knee and hip load — while still building cardiovascular base and lower-body endurance. Many patients report it simply does not hurt the way land-based exercise does at the start.
Fun-Based Movement
The most effective exercise for any individual is the one they will actually repeat. If "cardio" feels punitive, do not call it cardio. Dance-based movement delivers equivalent cardiovascular benefit with a fundamentally different psychological experience — enjoyment, novelty, and social energy rather than obligation and discomfort.
Task-Based Movement
Replacing "do 30 minutes of cardio" with a concrete, time-anchored micro-task eliminates the psychological weight of the open-ended goal. Patients who resist structured exercise often respond immediately to task framing — because it has a defined end point, and completion feels different from abandonment.
Clinicians who have prescribed GLP-1 medications extensively often delay structured exercise pressure until 20–30 lb of weight loss has occurred — not because movement is less important early, but because shame and guilt-driven goal-setting consistently backfires. The first goal is to establish any repeated movement habit, however small.
Progress is more meaningful than perfection. One woman on tirzepatide described stopping ten times in three miles, crying, and still continuing. That counts — fully.
These questions — drawn from motivational interviewing approaches used in clinical practice — are designed to help you identify your own reasons for moving, rather than following someone else's.
How could more physical activity improve your health, your wellbeing, and the things you are actually able to do each day?
What kind of movement would you choose to do, if it did not have to look like exercise?
What is the one barrier that keeps coming up — and what is the smallest possible version of overcoming it?
Whether you are talking to yourself or someone you care about — these framings tend to land better than standard encouragement.
"The medication wipes you out, and the treadmill sounds awful right now. That's real — and it's allowed."
"What if we just put shoes on and step outside for two minutes? We can come back after the mailbox."
"You said you want more energy for your kids. Muscle is what gives you that — not just the number on the scale."
"You showed up. That is the hardest part — and you did it. Motivation usually follows action, not the other way around."
The Clinical Bottom Line
The injection handles appetite. Exercise is what protects your muscles, preserves your fitness, sustains metabolic health, and keeps the weight off when the medication eventually changes or stops. You do not need to enjoy it yet. You do not need to do much of it yet. You need a habit — something repeated, however small, that becomes the foundation for everything else. Start with five minutes. Start with a song. Start with the end of the street. Start today.
Body & Skin Changes
Rapid weight loss — not the drug itself — causes skin laxity, volume loss, and structural changes. Understanding why helps you prevent and manage them proactively.
Subcutaneous Fat Loss
The fat pads under your skin (cheeks, temples, orbit) that give a "plump, filled-in" look are lost preferentially. GLP-1s cause global fat reduction — including the face.
Lean Mass Loss
Without resistance training, 25–40% of GLP-1 weight loss is muscle. Less facial and body muscle means less structural support for overlying skin.
Collagen & Elastin Decline
Rapid weight loss accelerates breakdown of these structural skin proteins. The skin's ability to "spring back" diminishes, especially in older adults.
Dehydration
GLP-1s reduce hunger and thirst cues. Many patients drink less water, leading to dull, textured, aged-looking skin that exaggerates laxity.
Face
"Ozempic Face" — cheeks, temples, under eyes, jowls. Most reported and fastest to show.
Neck & Jowls
Platysmal bands, turkey neck, loss of jawline definition.
Upper Arms
"Batwing" laxity from fat + muscle volume loss.
Abdomen
Pannus skin loosening after large abdominal fat volume loss.
Thighs & Buttocks
"Ozempic butt" — flat, deflated gluteal appearance from fat loss.
Hands
"Ozempic hands" — prominent tendons and veins as dorsal fat disappears.
Slow the Weight Loss Rate
Target 0.5–1 lb/week, not 2–3 lbs. Discuss your dose escalation pace with your clinician. "The faster you lose, the more likely your face and skin will show it." Tirzepatide produces greater total loss than semaglutide — manage accordingly.
Protein + Resistance Training
Minimum 1.2 g/kg body weight daily (some clinicians recommend up to 1 g/lb target weight). Strength train 2–4× per week — muscle supports skin. Without both, you risk a "skinny-fat" body composition with pronounced laxity.
Hydration — 1.5–2 L/day
GLP-1s blunt thirst. Actively track your water intake. Dehydrated skin looks older, more textured, and exaggerates any existing laxity.
Collagen Support
Vitamin C-rich foods promote collagen synthesis. Collagen peptide supplements (10–15 g/day) have emerging evidence. Daily moisturiser and SPF 30+ minimise photo-ageing on top of weight-loss changes.
See a Dermatologist Early — "Prejuvenation"
Derms now offer GLP-1 "prejuvenation" protocols — starting collagen-stimulating treatments before significant volume loss occurs. Earlier intervention produces better outcomes than later correction.
Daily Skin Routine
Prevention ("Prejuvenation")
Before significant volume loss — best outcomes
Sculptra / PRF
Biostimulators that trigger your own collagen production over 2–3 months. Initiated early, they build a collagen reserve that resists future volume loss.
Radiesse Filler
Calcium hydroxyapatite filler that restores mid-face volume and also stimulates collagen. Often used preventatively in GLP-1 patients starting treatment.
Baby Botox
Low-dose preventative neuromodulator to reduce dynamic lines that become more visible as fat volume drops. Does not address laxity directly.
Non-Surgical Correction
If changes have already occurred
Dermal Fillers (HA)
Juvederm, Restylane — restore volume to cheeks, jawline, lips, tear troughs. Reversible with hyaluronidase. Results 12–18 months.
Microneedling + RF
Morpheus8, Sylfirm X — radiofrequency energy triggers collagen remodelling and skin tightening. 2–3 sessions for mild-to-moderate laxity.
Ultherapy / FaceTite
HIFU (Ultherapy) and radiofrequency-assisted lipolysis (FaceTite) for more pronounced skin laxity without surgery.
Micro/Nanofat Transfer
Autologous fat grafted to the face for natural volume restoration. Long-lasting, natural results — popular with plastic surgeons treating "Ozempic face."
Surgical Options
For pronounced laxity after large weight loss
Face & Neck Lift
SMAS facelift with or without neck lift for pronounced jowls, neck bands, and significant facial laxity. Most lasting correction for advanced cases.
Body Contouring
Arm lift (brachioplasty), tummy tuck (abdominoplasty), thigh lift — for loose skin on the body after 20+ kg total weight loss.
Fat Transfer to Face / Body
Structural fat grafting to restore volume to face, breasts, hands, or buttocks — natural fill using patient's own tissue.
Skin has more elastin and repair capacity. May retract reasonably well if weight loss is moderate (<15 kg) and the rate is slow (0.5–1 lb/week).
Partial retraction possible. Skin quality, genetics, smoking history, and sun damage all affect outcomes. Collagen support and non-surgical treatments improve results significantly.
Less likely to retract fully. Lower baseline fat reserves, natural collagen depletion, and age-related elastin decline mean skin changes are more likely to require active treatment.
Fat returns and often fills the skin back — face and body may regain previous appearance. However, weight regain carries significant cardiometabolic risks and is not a recommended management strategy.
GlantHealth Clinic Position on Cosmetic Concerns
We set expectations with all patients about the possibility of cosmetic changes before starting therapy. Managing the rate and extent of weight loss, optimising protein and resistance training, and early referral to an aesthetic dermatologist are our primary strategies. We do not directly provide aesthetic treatments, but can provide referral guidance. Cosmetic changes are a real consideration — and they should never be a reason to avoid medically necessary treatment for obesity or metabolic disease. Contact us to discuss your individual risk: WhatsApp +1 705-280-6886.
Clinic Services
Our clinic offers comprehensive tools to support your metabolic health journey — from precision body composition to personalised nutrition science.
We use the InBody bioelectrical impedance scale to go far beyond a standard weight measurement. This clinical-grade tool gives us a precise, segmental breakdown of your body's composition.
Why it matters on GLP therapy: Weight loss medications can reduce both fat and lean muscle. InBody scans help our team ensure you are losing fat — not muscle — and adjust your protein and exercise plan accordingly.
Our in-house diet coaching program supports you in building sustainable, nutrient-rich eating habits that complement your GLP therapy and protect against muscle loss.
Nutrigenomix is a clinically validated genetic test that analyses your DNA to reveal how your body uniquely responds to specific nutrients, foods, and dietary patterns.
Results are interpreted by our team to tailor your nutrition and GLP therapy plan to your unique genetic profile — a single test with lifelong value.
OHIP Coverage Note: Physician consultations related to obesity management may be covered by OHIP. InBody scans, diet coaching sessions, and Nutrigenomix genetic testing are not covered by OHIP and are billed directly. Please contact our clinic for current pricing and any available insurance options.
Women's Health Considerations
Important clinical guidance for women of childbearing age on GLP-1 and dual GLP-1/GIP therapies.
All women of childbearing potential should have a dedicated conversation about family planning goals before and during GLP therapy.
A highly effective, non-oral contraceptive method (IUD, implant, hormonal injection) is strongly recommended during GLP therapy.
Stopping GLP agents causes rapid weight regain. Plan any medication changes around pregnancy timing with your clinical team.
Untreated obesity carries its own pregnancy risks (gestational diabetes, pre-eclampsia). Shared decision-making is essential.
Patient Experience
You may be asked to work through a standard set of questions at your appointment. Reviewing these beforehand can help you prepare and reflect on your progress.
You may be asked to complete these questions after starting treatment. Reviewing them beforehand can help you reflect on how things have been going since your last dose or dose increase.
Category 1
Have you been taking your injection consistently each week?
Have you missed any doses since your last visit, and if so, how many?
Are you rotating your injection sites (abdomen, thigh, or upper arm)?
Have you noticed any redness, swelling, itching, or lumps at the injection site?
Category 2
Have you experienced nausea or vomiting since your last dose or dose increase?
Have you had diarrhoea — loose or watery stools more frequently than usual?
Have you had constipation — difficulty passing stools or fewer than normal?
Any worsening abdominal bloating or a persistent feeling of fullness between meals?
Category 3
How has your weight changed since your last visit — and how does this compare to your expectations?
Has your appetite changed — is it better controlled, or do you feel too suppressed to eat enough?
Have you noticed a reduction in food cravings or "food noise" — the persistent preoccupation with eating?
Category 4
Have you had any episodes of low blood sugar — shakiness, sweating, confusion, or racing heart? (Particularly relevant if you have type 2 diabetes.)
Have you had any severe or persistent abdominal pain, especially pain radiating to the back or shoulder?
Have you experienced any changes in vision, palpitations, chest discomfort, or sudden dizziness?
If you experience any of these symptoms acutely, do not wait for your next appointment — contact our clinic or seek emergency care.
Category 5
Have you been able to exercise regularly? Has your activity level increased, decreased, or stayed the same?
Has your ease of movement or physical function — stairs, walking distances, daily tasks — improved since starting treatment?
Overall, how would you rate your quality of life, energy levels, and mood compared to before you started therapy?
Why we ask
Quality of life and activity are core treatment outcomes — not just weight. Research shows that even modest improvements in physical function and mood can be early indicators of effective therapy and sustained long-term success.
Your Self-Assessment
Based on 0 responses — areas to discuss at your visit
Additional Side Effects
Clinically relevant side effects of GLP-1/GIP therapies that may not be widely discussed — what the evidence shows and how to manage them.
Skin Reactions · Tirzepatide
Injection-site reactions are the most common; generalised or systemic reactions are less frequent but require prompt assessment.
Reported Frequency
Injection-site reactions
vs. ~0.6% placebo
Generalised rash / hypersensitivity
>0.1% — listed in prescribing information
Angioedema / DRESS / anaphylaxis
Post-marketing reports
Severity Spectrum & Management
Injection-Site Reaction
Management
Delayed Hypersensitivity
Management
Systemic / Anaphylaxis
Management
Seek Emergency Care Immediately For
Sources: Tirzepatide (Mounjaro®/Zepbound®) prescribing information (Eli Lilly). SURMOUNT clinical trial program. Higher doses (10–15 mg) appear to correlate with more immune-mediated effects.
Alopecia · Both Agents
Hair loss reported with tirzepatide and semaglutide is driven by rapid weight loss — not direct follicle damage. It is temporary and reversible.
Telogen effluvium: follicles are not damaged. Hair regrows once the metabolic trigger resolves.
Frequency Data from Clinical Trials
| Drug | Reported Rate | Notes |
|---|---|---|
| Mounjaro® (tirzepatide) | 4.9–5.7% | Not in original FDA label; higher at 15 mg dose. vs. 0.9% placebo. |
| Zepbound® (tirzepatide) | 4–5% overall 7.1% females / 0.5% males |
Listed as a common side effect. No trial participants discontinued due to hair loss. |
| Wegovy® (semaglutide) | ~3% adults ~4% adolescents |
For comparison. Similar mechanism — rapid weight loss driven. |
Practical Management
Hit Protein Targets
Aim for 60–80 g/day minimum. Hair is made of keratin — a protein. Calorie restriction on GLP therapy can deplete intake.
Check Labs
Ferritin, iron, B12, vitamin D, zinc, and thyroid function. Correct any deficiencies identified.
Slow Titration
If weight loss exceeds 1–2 lb/week, consider holding at the current dose rather than escalating. Reduces metabolic stress signal.
Time is the Treatment
Shedding typically peaks and resolves. Full recovery usually occurs within 6 months after weight plateaus. Follicles are intact.
Reassess if Any of These Are Present
These patterns suggest alopecia areata, thyroid disease, or autoimmune cause — not telogen effluvium. Dermatology referral warranted.
Sources: Tirzepatide prescribing information (Zepbound®/Mounjaro®), Eli Lilly. 2022 SURMOUNT trial data. 2025 study (Mounjaro® and Saxenda® associated with higher severe hair loss rates vs. other GLP-1s).
Mental Health · FDA Meta-Analysis 2025
Earlier post-marketing signals prompted an FDA review. The most comprehensive analysis to date finds no increased risk — but clinical vigilance remains essential.
FDA Meta-Analysis Conclusion — No Increased Risk
A 2025 FDA meta-analysis of 91 randomised controlled trials involving more than 100,000 participants on GLP-1 and GLP-1/GIP receptor agonists found no statistically significant increase in the risk of suicidal ideation or suicidal behaviour compared with placebo. This is the most comprehensive safety review conducted to date.
How the Evidence Evolved
2023 — Initial Signal
European Medicines Agency (EMA) and FDA began investigating post-marketing reports of suicidal ideation in patients on semaglutide and liraglutide. Signal was based on spontaneous adverse event reports — subject to confounding by indication (obesity and diabetes are independently associated with depression and suicidality).
2023–2024 — Conflicting Data
Observational studies produced mixed results. Some suggested a possible protective effect (mood improvement with weight loss); others were inconclusive. The heterogeneity of study populations and baseline psychiatric history made interpretation difficult.
2025 — FDA Comprehensive Review
After reviewing 91 RCTs (>100,000 participants), the FDA concluded there is no increased risk of suicidal ideation or behaviour with GLP-1 or dual GLP-1/GIP receptor agonists. Prescribing information was not required to carry a specific suicide warning.
Clinical Guidance — Despite Reassuring Data
Treat suicidal ideation as a safety signal
New or worsening thoughts of self-harm during GLP therapy should be assessed promptly — regardless of causality. Do not attribute it to the medication or dismiss it without evaluation.
Medication review at every mental health visit
If suicidal ideation is present, the GLP agent should be considered for temporary hold while a full psychiatric assessment is completed — not because it is the likely cause, but as part of comprehensive management.
Use caution in patients with active psychiatric illness
Patients with active depression, bipolar disorder, or prior suicidal behaviour were often excluded from GLP-1 trials. The real-world safety profile in these populations warrants closer monitoring.
Contact our clinic or crisis services immediately
Any patient experiencing suicidal thoughts should contact our clinic promptly, or call 988 (Canada/USA Suicide Crisis Helpline). Do not wait for a scheduled appointment.
If You or Someone You Know Is in Crisis
Sources: FDA Drug Safety Communication (2025) — meta-analysis of 91 RCTs, >100,000 participants. EMA Safety Review (2023). Prescribing information for semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly).
SURMOUNT-5 Trial · 72 Weeks
The largest direct comparison trial of both agents, published 2024. Real clinical outcomes, side by side.
Semaglutide · 2.4 mg/week
Tirzepatide · 15 mg/week
Source: SURMOUNT-5 head-to-head randomised trial (2024), n=751 adults without diabetes. Results may vary by individual. Both medications require prescription and clinical supervision.
Canadian Clinical Context
In Canada, these are the diabetes-approved brand names. Understanding approved indications and real-world data is essential for informed prescribing and patient counselling.
42.3%
of Mounjaro® patients reached ≥15% weight loss
vs 18.1% with Ozempic®
6.9%
greater weight loss with Mounjaro® at 12 months
real-world head-to-head data
81.8%
of Mounjaro® patients lost ≥5% body weight in 1 year
vs 66.5% with Ozempic®
✓ CV + CKD
Ozempic® proven to reduce cardiovascular and kidney risk
Mounjaro® not yet approved for these indications
| Topic | Ozempic® (Semaglutide) | Mounjaro® (Tirzepatide) |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GLP-1 / GIP receptor agonist |
| Canadian Indication | Type 2 diabetes; CV risk reduction; slows kidney disease progression in T2D. Not approved for weight loss — Wegovy® is the weight-loss brand. | Type 2 diabetes only. Not approved for weight loss — Zepbound® is the weight-loss brand. |
| Weight-Loss Brand | Wegovy® | Zepbound® |
| Dosing Schedule | 0.25 mg × 4 wks → 0.5 → 1 → 2 mg/week max | 2.5 mg/week; ↑ by 2.5 mg every ≥4 weeks; max 15 mg |
| Pen Type | Multi-dose pens; replace needle each use | Single-use pens |
| Mechanism Advantage | Mimics GLP-1 only | Activates GLP-1 and GIP receptors — the additive GIP action is associated with greater appetite suppression and, at lower doses, reduced nausea compared with GLP-1 alone |
| A1C Reduction (SURPASS-2) | −1.86% with 1 mg | −2.01% to −2.30% with 5–15 mg; nearly 2× as many Mounjaro® patients reached A1C <5.7% (near-normal) compared with Ozempic® |
| Weight Loss (T2D patients) | ~13 lb avg (SURPASS trials); 66.5% lost ≥5% body weight at 1 year (EHR study, n=18,386) | 12–25 lb avg (SURPASS trials); 81.8% lost ≥5% at 1 year; 42.3% lost ≥15% vs 18.1% with Ozempic® (EHR study, n=18,386) |
| CV & Kidney Benefit | ✓ Proven — FDA & Health Canada approved for CV risk reduction and slowing kidney disease progression in T2D | Studies ongoing — not yet approved for CV or CKD outcomes; data expected in coming years |
| Notable Side Effects | Nausea, diarrhea, vomiting, constipation; may cause more headaches than tirzepatide. GI symptoms are often triggered by overeating, given reduced gastric emptying. | Nausea, diarrhea, decreased appetite, vomiting, constipation. SURPASS-2: slightly higher rate of serious adverse events vs semaglutide. Higher doses (≥10 mg) can cause pronounced GI symptoms — slow titration is essential. |
| Interchangeability | These medications are not interchangeable. Switching directly between Ozempic® and Mounjaro® is not recommended — dosing, titration schedules, and receptor targets differ. Any switch requires clinical reassessment and re-titration under physician supervision. | |
| Boxed Warning (both) | Thyroid C-cell tumours in rodents (clinical significance in humans unknown). Pancreatitis, gallbladder disease, hypoglycemia, kidney injury. Both require prescription and ongoing medical supervision. | |
| Approx. Cash Price | ≈ $1,000+ / month CAD — savings cards available from manufacturers; coverage varies by province and private plan. | |
Novo Nordisk's Ozempic® patent expired in Canada in early January 2026. Health Canada has now authorized the first generic versions — a landmark for Canadian patients.
Health Canada Approved Generics
Dr. Reddy's Laboratories (India)
Approved April 28, 2026
Covers 2 mg/pen and 4 mg/pen (1.34 mg/mL) formulations
Apotex (Canada 🇨🇦)
Approved May 1, 2026
Canadian-based manufacturer; second authorized generic
Seven additional submissions under review at Health Canada — including Sandoz Canada, Taro Pharmaceuticals, Aspen Pharmacare, and Teva Canada. Further approvals expected in the coming weeks and months.
Cost Comparison — Brand vs. Generic (CAD)
Brand Name — Current
Generic Semaglutide — Projected
Generic ≠ Wegovy®. Approved generics are equivalent to Ozempic® (the diabetes-dose formulation). There is currently no approved generic equivalent to Wegovy® (the 2.4 mg/week weight management dose). Patients using semaglutide specifically for weight management should discuss options with their physician.
Coverage. Most public and private drug plans currently cover Ozempic® for Type 2 diabetes only. Generic coverage and formulary listing decisions vary by province and insurer — check with your plan directly.
Pharmacy availability. Generics are Health Canada–authorized, but pharmacy shelves and supply chains are still ramping up. Significant availability and price drops are expected through mid-to-late 2026. No generic tirzepatide (Mounjaro®/Zepbound®) has been approved.
Sources: Health Canada (April 28 & May 1, 2026), CBC News, Global News. Pricing estimates from University of Toronto drug policy research (Tadrous) and McGill University. Prices are approximate and will vary by province and pharmacy.
Important Clinical Points
Starting or continuing GLP-1 therapy is a meaningful step — and it takes real courage to prioritise your health. Whatever brought you here, we want you to know that this journey is worth it, and you deserve the very best support along the way.
Progress, not perfection. Every small step — a better meal, a short walk, remembering your dose — is moving you forward.
You are supported. Our clinical team is here at every visit, and on WhatsApp between appointments — you don't have to figure this out alone.
Give it time. The research is clear — results build steadily over months. Trust the process, stay consistent, and the outcomes follow.
"Obesity is a chronic medical condition — not a personal failing. Seeking treatment is strength, not weakness."
From everyone at GlantHealth Metabolic Medicine — we are rooting for you. 💙
Our Clinical Team
GlantHealth Metabolic Medicine is a specialist clinic dedicated to evidence-based obesity and metabolic medicine. Every patient is seen, assessed, and followed by our clinicians — not delegated to an algorithm.
MD · Specialist in Obesity & Metabolic Medicine
Dr. Haroon leads the clinical programme at GlantHealth Metabolic Medicine, bringing specialist expertise in obesity medicine, metabolic disease, and evidence-based pharmacotherapy. She oversees all patient assessments, GLP-1 and GLP-1/GIP prescribing decisions, titration protocols, and ongoing monitoring — ensuring every patient receives personalised, clinically rigorous care rather than a one-size-fits-all approach.
Her clinical philosophy centres on treating obesity as the chronic, complex medical condition it is — addressing appetite neurobiology, metabolic adaptation, body composition, and patient wellbeing together. She works closely with each patient to set realistic goals, manage side effects proactively, and adjust therapy in response to their individual response over time.
Evidence-Based
Prescribing grounded in RCT data from STEP, SURMOUNT, and SELECT trials
Whole-Person Care
Nutrition, body composition, mental wellbeing, and metabolic markers — all assessed together
Ongoing Monitoring
Serial InBody scans, labs, and follow-up visits track muscle preservation, not just weight
Patient Partnership
You set the pace — we provide the clinical framework, safety guardrails, and support
Behind every consultation is a coordinated team — clinical coordinators, diet coaches, and administrative staff — who ensure your care journey is smooth, responsive, and well-supported between visits.
Clinical Coordinators
Manage your visit schedule, prescription renewals, and follow-up reminders
Diet & Nutrition Coaches
Protein targeting, meal planning, and micronutrient support tailored to GLP-1 therapy
WhatsApp Triage Line
Direct access to the team for questions, side-effect concerns, and urgent guidance between visits
Our clinical team will evaluate your history, goals, and medical background to recommend the right agent and personalised plan for you.
Chat with our clinic on WhatsApp
+1 (705) 280-6886
Tap the button below — our team typically responds within a few hours during clinic hours.
Educational Purpose Only
All content on this website — including text, tables, graphics, dosing information, clinical summaries, and safety guidance — is provided for general educational and informational purposes only. It does not constitute, and must not be used as a substitute for, professional medical advice, clinical diagnosis, or treatment recommendations.
No Physician–Patient Relationship
Accessing or reading this website does not create a physician–patient relationship between you and GlantHealth Metabolic Medicine or any of its clinicians. Personalised medical decisions — including whether to start, continue, adjust, or stop any medication — must be made in consultation with a licensed healthcare provider who can assess your individual circumstances.
Not a Replacement for Drug Monographs
Clinical summaries on this site are intended to supplement, not replace, the official Canadian prescribing information (product monographs) for semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). Prescribers and patients should refer to the current approved monograph for complete prescribing, safety, and contraindication information.
Currency of Information
Medical knowledge, Health Canada authorizations, clinical guidelines, and drug pricing evolve rapidly. While we strive to keep content current and accurate, GlantHealth Metabolic Medicine does not warrant that all information is up to date at the time of access. Content referencing recent approvals (e.g., generic semaglutide, May 2026) reflects information available at the time of publication and may have changed.
No Emergency Medical Advice
This website is not designed to address medical emergencies. If you are experiencing a medical emergency — including symptoms of anaphylaxis, angioedema, severe chest pain, or any condition requiring urgent care — call 911 or proceed to your nearest emergency department immediately. Do not rely on website content in an emergency.
Canadian Context
Content is written primarily for a Canadian patient and clinical audience and reflects Health Canada–approved indications, pricing, and regulatory status where noted. Drug availability, insurance coverage, and approved indications vary by country. Patients outside Canada should consult local regulatory and prescribing guidance.